JP2017522277A5 - - Google Patents

Download PDF

Info

Publication number
JP2017522277A5
JP2017522277A5 JP2016570862A JP2016570862A JP2017522277A5 JP 2017522277 A5 JP2017522277 A5 JP 2017522277A5 JP 2016570862 A JP2016570862 A JP 2016570862A JP 2016570862 A JP2016570862 A JP 2016570862A JP 2017522277 A5 JP2017522277 A5 JP 2017522277A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
alkyl
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016570862A
Other languages
English (en)
Japanese (ja)
Other versions
JP6552061B2 (ja
JP2017522277A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/034964 external-priority patent/WO2015191630A1/en
Publication of JP2017522277A publication Critical patent/JP2017522277A/ja
Publication of JP2017522277A5 publication Critical patent/JP2017522277A5/ja
Application granted granted Critical
Publication of JP6552061B2 publication Critical patent/JP6552061B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016570862A 2014-06-10 2015-06-09 代謝型グルタミン酸受容体の負のアロステリックモジュレーター(nams)とその使用 Active JP6552061B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462009910P 2014-06-10 2014-06-10
US62/009,910 2014-06-10
PCT/US2015/034964 WO2015191630A1 (en) 2014-06-10 2015-06-09 Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof

Publications (3)

Publication Number Publication Date
JP2017522277A JP2017522277A (ja) 2017-08-10
JP2017522277A5 true JP2017522277A5 (enExample) 2018-07-19
JP6552061B2 JP6552061B2 (ja) 2019-07-31

Family

ID=54834213

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016570862A Active JP6552061B2 (ja) 2014-06-10 2015-06-09 代謝型グルタミン酸受容体の負のアロステリックモジュレーター(nams)とその使用

Country Status (6)

Country Link
US (4) US9969726B2 (enExample)
EP (1) EP3154954B1 (enExample)
JP (1) JP6552061B2 (enExample)
AU (1) AU2015274781C1 (enExample)
CA (1) CA2950952C (enExample)
WO (1) WO2015191630A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10099993B2 (en) * 2014-04-06 2018-10-16 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor positive allosteric modulators (PAMS) and uses thereof
US9969726B2 (en) 2014-06-10 2018-05-15 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (NAMS) and uses thereof
HRP20191327T1 (hr) 2015-06-03 2019-11-01 Bristol Myers Squibb Co 4-hidroksi-3-(heteroaril)piridin-2-on apj agonisti za primjenju u liječenju kardiovaskularnih poremećaja
CN108299303B (zh) * 2018-02-09 2022-10-11 中山大学 一种四芳基吡唑类化合物的合成新方法
CN108997325B (zh) * 2018-07-06 2020-08-04 浙江工业大学 一种芳基联噻唑类化合物和应用
EP3829567A4 (en) * 2018-07-27 2022-05-04 With Great Power, LLC CLINICAL METHODS AND PHARMACEUTICAL COMPOSITIONS WITH AMPA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF GLIOBLASTOMA AND OTHER CARCINOMAS
US12366579B2 (en) * 2019-03-21 2025-07-22 University Of Virginia Patent Foundation Sulfur-heterocycle exchange chemistry and uses thereof
CN110183382A (zh) * 2019-06-06 2019-08-30 东北师范大学 新型三氟甲基吡唑类化合物合成方法
WO2021016256A2 (en) * 2019-07-22 2021-01-28 Angion Biomedica Corp. Ethynylheterocycles as rho-associated coiled-coil kinase (rock) inhibitors
US20230119479A1 (en) 2019-12-10 2023-04-20 Shionogi & Co., Ltd. A histone deacetylase inhibitor having a nitrogen-containing aromatic heterocyclyl group
WO2022056447A1 (en) * 2020-09-14 2022-03-17 Genzyme Corporation Carboxylic acid-containing compounds as modulators of bis-phosphoglycerate mutase for the treatment of sickle cell disease
CN112480073B (zh) * 2020-12-02 2022-03-22 武汉药明康德新药开发有限公司 1-烷基-3,5-芳基取代的1,2,4三氮唑化合物的合成方法
US20220265601A1 (en) * 2021-02-10 2022-08-25 David Alan Heldreth, JR. Methods of use and formulations of allosteric modulators of the serotonin, dopamine and other receptor systems for medical, recreational, religious, research and other uses.
CN116041277B (zh) * 2023-01-18 2024-11-01 中国药科大学 苯基和联苯基取代的五元杂环类化合物及其制备方法、药物组合物和应用
US11970460B1 (en) 2023-10-24 2024-04-30 King Faisal University 4-(4,5-bis(4-bromophenyl)-2-phenyl-1H-imidazol-1-yl)benzoic acid as an antimicrobial compound
WO2026064466A1 (en) * 2024-09-19 2026-03-26 The University Of North Carolina At Chapel Hill Compositions and methods for treating pain

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU779874B2 (en) 1999-10-15 2005-02-17 F. Hoffmann-La Roche Ag Benzodiazepine derivatives
TR200201023T2 (tr) 1999-10-15 2002-09-23 F. Hoffmann-La Roche Ag Benzodiazepin türevleri.
PL369598A1 (en) * 2001-02-21 2005-05-02 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
HRP20030791B1 (en) * 2001-04-12 2006-06-30 F. Hoffmann - La Roche Ag DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS mGluR2 ANTAGONISTS I
EP1379511B1 (en) * 2001-04-12 2005-07-20 F. Hoffmann-La Roche Ag DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II
WO2002096905A1 (en) * 2001-06-01 2002-12-05 Vertex Pharmaceuticals Incorporated Thiazole compounds useful as inhibitors of protein kinases
US6949542B2 (en) 2002-02-06 2005-09-27 Hoffman-La Roche Inc. Dihydro-benzo[b][1,4]diazepin-2-one derivatives
EP1485093B1 (en) 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5
BR0317430A (pt) * 2002-12-20 2005-10-25 Pharmacia Corp Compostos inibidores de quinase-2 de proteìna ativada por quinase de proteìna ativada por mitógeno
JP2006522128A (ja) * 2003-04-03 2006-09-28 メルク エンド カムパニー インコーポレーテッド 代謝調節型グルタミン酸受容体−5のモジュレーターとしての4環イミダゾール誘導体
JP2006528617A (ja) * 2003-07-24 2006-12-21 ファーマジーン ラボラトリーズ リミテッド 5−ht2b受容体アンタゴニスト
MXPA06013250A (es) * 2004-05-14 2007-02-28 Abbott Lab Inhibidores de quinasa como agentes terapeuticos.
KR101363278B1 (ko) * 2005-06-27 2014-02-21 엑셀리시스 페이턴트 컴퍼니 엘엘씨 이미다졸계 lxr 변조제
MX2008012413A (es) * 2006-03-29 2008-10-07 Hoffmann La Roche Derivados de piridina y pirimidina como antagonistas del receptor metabotropico de glutamato 2 (mglur2).
US8012986B2 (en) * 2007-04-02 2011-09-06 Hoffmann-La Roche Inc. Pyridine and pyrimidine derivatives as MGLUR2 antagonists
EP2145873A1 (fr) * 2008-06-17 2010-01-20 Commissariat A L'energie Atomique Nouveaux composés ayant une activité protectrice vis-à-vis de l'action de toxines et de virus au mode d'action intracellulaire
JP5859454B2 (ja) * 2009-12-14 2016-02-10 メルク・シャープ・エンド・ドーム・ベー・フェー Mk2インヒビター
WO2011116356A2 (en) * 2010-03-19 2011-09-22 Sanford-Burnham Medical Research Institute Positive allosteric modulators of group ii mglurs
US9193710B2 (en) 2011-08-29 2015-11-24 Sanford-Burnham Medical Research Institute Benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof
GB201321743D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
US9969726B2 (en) 2014-06-10 2018-05-15 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (NAMS) and uses thereof

Similar Documents

Publication Publication Date Title
JP2019524883A5 (enExample)
JP2019516739A5 (enExample)
JP2013519675A5 (enExample)
JP2015516427A5 (enExample)
JP2013509429A5 (enExample)
JP2014506907A5 (enExample)
JP2013032389A5 (enExample)
JP2020532547A5 (enExample)
JP2012144574A5 (enExample)
JP2014508811A5 (enExample)
JP2014511891A5 (enExample)
JP2014508753A5 (enExample)
JP2014507455A5 (enExample)
JP2013518107A5 (enExample)
JP2017514910A5 (enExample)
JP2018510138A5 (enExample)
JP2012092103A5 (enExample)
JP2019531279A5 (enExample)
JP2012255026A5 (enExample)
JP2017509689A5 (enExample)
JP2015508092A5 (enExample)
JP2019520344A5 (enExample)
JP2014507477A5 (enExample)
JP2018502824A5 (enExample)
EA201070783A1 (ru) 1,2,4-оксадизольные соединения для лечения аутоиммунных заболеваний